## 3 Results  
Fourteen ASA I-II patients previously rehabilitated with a zirconia ISFCDP were included in the study and recalled for a follow-up visit. The 14 patients, 5 males and 9 females, were between 52 and 80 years of age (average of 64 \(\pm\) 8.5 years), and were rehabilitated with 14 ISFCDPs (86 implants in total). Seven out of fourteen patients were light smokers (50%), whilst one patient was affected by diabetes (7.1%), three patients suffered from hypertension (21.4%), and two patients had previous myocardial infarction (14.3%). Ten out of fourteen patients received a maxillary ISFCDP, while four patients received a mandibular ISFCDP. All ISFCDPs were supported by a minimum of four to a maximum of eight implants. The mean follow-up time at the time of the recall was 36 \(\pm\) 10 months (Table 1). Regarding the technique used to produce the ISFCDP, five were produced using the zirconia-on-titanium technique, four using the progressive monolithic zirconia technique, and five using the zirconia-on-zirconia technique. The presence of purulent discharge was reported in three implants (3.49%) supporting a mandibular full arch zinc-on-zirc ISFCDP in a smoker patient. Regarding probing depth, six implants (6.98% of all implants) had 5 mm of probing depth or more in at least one site: four implants were part of the same rehabilitation on a smoker patient, while the remaining two implants were each part of two other ISFCDPs in non-smoker patients. Local signs of inflammation were observed in two implants (2.33% of the total), both part of the same rehabilitation on a smoker patient. Bleeding on probing was reported in five patients out of fourteen (35.6%), who had a bleeding site on at least one implant; the worst case was on a smoker patient with BoP on 20 sites of a total of eight implants, with a BoP of 41%. The second patient showed bleeding on two sites of two implants (5.5% BoP); the third patient on two sites of two implants with 4.7% BoP. The remaining two patients both showed bleeding on one site on one implant with 2.7% BoP. The mean BoP value, including the smoker patient with a high percentage of BoP-positive sites, was 13.48 \(\pm\) 15,9%. One prosthetic complication was reported (7%): one zirconia-on-zirconia ISFCDP was affected by one instance of chipping in a site corresponding to pink gingiva and was repaired intraorally using pink composite. Six out of fourteen patients showed at least one site of implant spire exposure, but all exposed sites were less than 1 mm in length. All the complications at implant and prosthetic level are shown in Table 2.  
The overall prosthetic success rate was 92.86%, with a survival rate of 100% and an absence of failures, whilst the implant success was 95.35%, with a survival rate of 100%. Finally, 78.57% of the patients declared they were completely satisfied with the results obtained, 14.53% declared themselves to be very satisfied and 7.14% declared themselves to be satisfied; in addition, all patients would recommend rehabilitation with ISFCDPs (Table 3, Table 4). \begin{table}
\begin{tabular}{c c} \hline
**Sample Characteristics** & **Number** \\ \hline Number of Patients & 14 \\ Males & 5 \\ Females & 9 \\ Mean Age & 64 \\ Number of ISFCDPs & 14 \\ Maximally ISFCDPs & 10 \\ Mandibular ISFCDPs & 4 \\ Maximally Zirc-on-Zirc ISFCDPs & 3 \\ Mandibular Zirc-on-Zirc ISFCDPs & 2 \\ Maximally Progressive Monolithic Zirconia ISFCDPs & 3 \\ Mandibular Progressive Monolithic Zirconia ISFCDPs & 0 \\ Maximally Zirconia-on-Titanium ISFCDPs & 4 \\ Mandibular Zirconia-on-Titanium ISFCDPs & 2 \\ Number of Implants & 86 \\ Mean Follow-up Time (Months) & 36 \\ \hline \end{tabular}
\end{table} 
Table 1: Patient and implant characteristics.